logo
  

Stock Alert: TCR2 Therapeutics Up 35%

Shares of TCR2 Therapeutics Inc. (TCRR) are currently gaining over 35% on Monday morning. The clinical-stage company announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors.

TCRR is currently trading at $17.93, up $4.83 or 36.87%, on the Nasdaq.

TCR2 Therapeutics is a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer. It announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors.

All five patients showed tumor regression including two RECIST unconfirmed partial responses and two patients with stable disease through six months.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Bank of America Corp. (BAC) reported Thursday that net income applicable to common shareholders for the fourth quarter grew 30 percent to $6.77 billion from last year's $5.21 billion, with earnings per share increasing to $0.82 from $0.59 in the prior year, reflecting strong operating leverage as revenues... Shares of ASML Holding N.V. were gaining more than 1 percent in Amsterdam trading after the Dutch semiconductor equipment maker reported Wednesday higher profit and net sales in its fourth quarter. The company also projects higher sales in fiscal 2022, and a 100 percent increase in total dividend. Coffee giant Starbucks has expanded its delivery and online services in China through a partnership with e-commerce platform for services, Meituan. The three new and expanded services in offer would allow customers to connect with their local stores as well as curate an individual Starbucks Experience both online and offline.
Follow RTT